Showing posts with label Theralase. Show all posts
Showing posts with label Theralase. Show all posts

Thursday, May 30, 2013

Theralase Releases Financial Results for First Quarter 2013

Toronto, Ontario – May 30, 2013, Theralase Technologies Inc. (TSXV: TLT) released its first quarter 2013 financial results today, demonstrating an increase in profitability by 27% year over year, while successfully advancing its patented therapeutic laser and cancer destruction technologies .

Total revenue for the three months ended March 31, 2013 decreased to $342,900 from $448,359 for the same period in 2012, a 24% decrease.

Selling expenses decreased by 42%, to $109,391 from $188,390 for the same period in 2012. The percentage decrease was due to reduced spending on salaries on sales personnel and a reduction in marketing costs. 

Administrative expenses decreased by 19% to $249,767 from $309,213 for the same period in 2012.  The decrease in administrative expenditures is due to reductions in administrative personnel compensation, stock based compensation and rent. 

Research and development costs decreased to $199,597 from $249,158 for the same period in 2012. This represents a 20% decrease in expenditures, due to the approaching completion of research and development costs of the patented TLC-2000 therapeutic laser technology. 

The net loss for three month period ended March 31, 2013 was $332,435, which included $56,829 of net non-cash expenses compared to a net loss in 2012 of $453,285, which included $84,313 of net non-cash expenses, demonstrating an improvement of 27% year over year.

The net loss is a reflection of the ongoing commitment of Theralase to invest in the next level of therapeutic laser and cancer destruction technologies, from existing therapeutic laser sales. 

“Theralase is preparing for the launch of its next generation patented TLC-2000 biofeedback therapeutic laser technology in 4Q2013 that will revolutionize the therapeutic laser industry,” stated Roger Dumoulin-White, President and CEO of Theralase.  “In addition our cancer technology has evolved past the proof of concept stage and is now being readied for investigation in the destruction of bladder cancer in humans in 2014.

About Theralase Technologies Inc.

Theralase Technologies Inc. designs, manufactures and markets patented, superpulsed laser technology used in healing injured tissue and destroying cancer.  Theralase technology is safe and effective in eliminating pain, reducing inflammation and accelerating tissue regeneration of numerous nerve, muscle and joint injuries. Theralase is actively developing patented technology that is able to target and destroy cancers, bacteria and viruses when light activated.

The complete interim consolidated financial statements and MD&A for three month period ending March 31, 2013 may be viewed at www.theralase.com and www.sedar.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information, please contact:

Roger Dumoulin - White,                                                                  
President & CEO                                                                                
416-699-LASE (5273) ext. 225                                                                       
rwhite@theralase.com

Kristina Hachey
Chief Financial Officer
416-699-LASE (5273) ext. 224
khachey@theralase.com                                                                  

Greg Bewsh
Director of Investor Relations
416-699-LASE (5273) ext. 258

gbewsh@theralase.com   

Thursday, May 23, 2013

What is Cold Laser Therapy?

Cold laser treatment methods is a somewhat innovative technology when compared to the a great number of alternative therapies such as acupuncture (that's been practiced since 8000-3500 B.C.), chiropractic (since 1895) as well as physical therapy. Just like the abacus evolved into the computer, a variety of alternative medicine practices are expanding to also include light therapy. More recent advancements in low-level lasers now make it possible for the average medical professional or individual to own cold laser equipment. Cold lasers are sometimes called Low Level Lasers (LLL) or soft lasers.

Cold Laser treatment offers a non-intrusive option to acupuncture and surgery. It additionally allows for a non-addicting treatment which usually eliminates the complications associated with long-term medication treatment programs. Cold lasers tend to be commonly utilized for treatment associated with: Acute and chronic joint pain, Tendon strains, Muscle strain, Soft tissue injuries, Tendonitis, Arthritis, Tennis elbow, Back soreness, Bursitis, Carpal Tunnel Syndrome, in addition to Fibromyalgia.

In general, cold lasers usually are implemented in 2 specific methods. One is in fact Targeting acupuncture trigger points (analogous to acupuncture however minus the needles) and the other is actually by using Wide coverage of deep tissue with laser photons in order to spark changes within the tissue.

The cold laser creates an impulse of light at a specific wave length (typically 905nm) which will diminishes reflection in addition to scattering but maximized absorption of the energy (in photons) at a desire depth.

Various conditions such as joint pain involve a deep penetration (4-5 inches) that can only be accomplished using a super-pulsed laser emitter. Many systems also contain other lower wavelengths in addition to lower-power emitters for treating shallow tissue (like the lymph system or even surface scars). In addition, red light diode with a wave length of 660 nm could be utilized to add energy to even shallower levels of tissues. It is definitely the over-all judgement that wavelengths less than 660 nanometers are usually very easily absorbed within the surface tissue and are not optimized pertaining to deep tissue healing.

The purpose of laser therapies is to provide light energy units via infrared laser radiation, referred to as photons, to damaged cells. It is the preference of industry experts is that photons absorbed by the cells by way of laser therapy stimulate the mitochondria to boost production of ATP. This specific biochemical increase in cell energy can be utilized to enhance live cells from a state connected with illness to a stable, healthy state.

About 4000 reports have actually been performed in recent years to actually validate the effectiveness regarding cold laser therapies. The following actually are some of the particular advantages connected with Cold Laser Therapies. The therapy is definitely simple to implement, very safe, non-toxic, non-invasive, zero side effects or discomfort, cost effective with regard to both the practitioner and patient, particularly effective in treating ailments (more than 90% efficacy), superior alternative to pain killers, reduces the need regarding surgery, and often will work synergistically along with other modalities such as Chiro, Acupuncture, as well as Rehabilitation.

At this time, lasers are employed substantially in the medical industry intended for everything from cosmetic surgery, eye surgery and also heart surgery. The particular ability to place merely the right amount of energy straight into a vital spot of the human body is a fantastic advancement throughout the medical field. Cold lasers are usually an essential addition to these various other established medical laser treatments and the recent development involving  professional cold lasers suggests that cold laser therapy will probably be a rapidly growing non-invasive medical treatment option.


For more information please call 1-866-843-5273 or visit www.theralase.com 

Thursday, May 2, 2013

Theralase Announces 2012 Year End Financials


Theralase Advances Therapeutic Laser and Cancer Destruction Technologies

Toronto, Ontario – May 1, 2013, Theralase Technologies Inc. (TSXV: TLT) announced its year end 2012 financial results today.

Total revenue for the twelve month period ended December 31, 2012 dipped slightly to $1,824,313 compared to $2,027,058 for the same period in 2011, a 10% reduction, primarily due to a reduction in laser sales in the US and internationally. In 2012, Theralase focused its efforts on laser sales in Canada for its Therapeutic Laser Technology (TLT) Division and for accelerating the research and development of its patented cancer destruction platform for its Photo Dynamic Therapy (PDT) Division.

Selling expenses decreased by 41%, to $626,380 for the twelve month period ended December 31, 2012 compared to $1,060,288 for the same period in 2011. The percentage decrease was due to decreased spending on salaries, marketing, advertising and travel related expenses, as more focus was paid to completing sales in Canada, than abroad. 

Administrative expenses increased from $1,028,431 for the twelve months ended December 31, 2011 to $1,238,900 for the same period in 2012 representing an increase of 20%. The increase in administrative expenditures was primarily due to increases in the costs associated with stock based compensation.

Research and development costs increased to $873,335 for the year ended December 31, 2012 compared to $759,352 for the previous year, representing a 15% increase, due in part to the costs required to commercialize the TLC-2000 biofeedback laser, but primarily due to research and development costs of the TLC-3000 Photo Dynamic Compound (PDC) cancer and bacteria destruction technology.

The net loss for the year ended December 31, 2012 was $1,509,569, which included $322,915 of net non-cash expenses (amortization, stock-based compensation expense, foreign exchange gain/loss, equipment write-off and lease inducements) compared to a net loss in 2011 of $1,453,974, which included $74,921 of net non-cash expenses.  The increase in net loss is due to  increases in the costs associated with stock based compensation, commercialization of the patented TLC-2000 Biofeedback Therapeutic Laser due for launch in 2013 and primarily due to the research and development of the TLC-3000 Photo Dynamic Compound cancer destruction technology due for completion of the pre-clinical phase by 4Q2013.

Theralase has had many successes in 2012, specifically:
  • Preclinical research that confirmed the complete destruction of subcutaneous (under the skin) colon cancer tumours in mouse subjects, which were treated with the Theralase anti-cancer Photo Dynamic Compound (PDC) technology, which have continued to thrive cancer-free for more than 1 year post-treatment without any side effects.
  • Bladder cancer named as the principal cancer target
  • Theralase’s PDC was found to be 100% effective in destroying bladder cancer tumour cells
  • Theralase PDCs have shown an ability to destroy Escherichia Coli (E. coli) and Listeria Monocytogenes (Listeria) bacteria in vitro when light activated
  • Theralase establishes laser distributors in the Middle East and China
  • Addition of TENS (Transcutaneous Electrical Nerve Stimulation) on select laser models to allow additional CPT billing codes for the US market
  • Theralase's innovative anti-cancer PDC technology validated at major international conferences
  • Theralase expands intellectual property portfolio with increased patent protection
  • Renowned oncologist Dr. Michael Jewett joins Theralase's medical and scientific advisory board

Roger Dumoulin-White, President and CEO of Theralase Technologies Inc. stated, “The Company has completed the research and development of its next generation, patented TLC-2000 Biofeedback Therapeutic Laser and is now preparing for its launch in 4Q2013. In addition, Theralase has made great strides forward in the research and development of its patented Photo Dynamic Compounds (PDCs), indicated for the destruction of specific cancerous tumours. Our first target, bladder cancer, should be ready for human trials as early as 2014. In order to capitalize on this state-of-the-art cancer destruction technology and dramatically increase shareholder value, Theralase is in negotiations with strategic partners focused on the early commercialization of this ground breaking technology.”


About Theralase Technologies Inc.

Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. As well, these applications extend to the care of animals by veterinarians. Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary laser technology.

The complete consolidated financial statements and MD&A for twelve months ending December 31, 2012 may be viewed at www.theralase.com  and www.sedar.com .

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information, please contact:

Roger Dumoulin-White,                                                                              
President & CEO                                                                                           
416-699-LASE (5273) ext. 225                                                                                  

Kristina Hachey
Chief Financial Officer
416-699-LASE (5273) ext. 224
khachey@theralase.com                                                                             

Greg Bewsh
Director of Investor Relations
416-699-LASE (5273) ext. 258

Arkady Mandel
Chief Scientific Officer
416-699-LASE (5273) ext. 260

Friday, April 26, 2013

COLD LASER THERAPY BASICS


Over 75 Trillion cells in a human body and they all need energy and electrons to communicate with each other. Laser light delivers the required electrons and energy directly to the cells, enhancing their ability to communicate with each other, absorb oxygen and nutrients and dispose of wastes and toxins. The laser delivers photons to the cells, and mitochondria, which they convert into ATP and use as energy for rebuilding and repairing tissues, tendons, ligaments, nerves and even bones.
Laser therapy is an exciting and relatively new field that can offer people a very safe and effective option to help with speeding up injury repair and reducing pain. provides a unique alternative to patients who are terrified of surgery or drugs, but still seek the powerful healing benefits.
A laser is defined as a device that produces intense radiation in the visible or near visible wavelengths.   Laser light is unique in that it is close to one specific wavelength and propagates in-phase; meaning that all of the electro-magnetic waves oscillate together in an ordered and aligned way.  Together, these conditions make up the term coherency.  When the coherent light is columnated, it can travel vast distances with very  little loss of power or scattering
Laser treatment used for healing is called “low-level laser” or “cold-laser” therapy.  By definition, lasers used for cold-laser therapy range in power from 5 to 500 milliwatts (0.005 to 0.5 Watts).  Lasers less than 5 milliwatts lack the power to induce a bio-stimulatory effect, while lasers greater than 500 milliwatts may cause excessive heating and burn the skin. Lasers used for surgery, however, range from 5 to 50 Watts
Approximately 3,000 clinical studies worldwide have attested to the beneficial and curative effects of therapeutic lasers. 

Cold-laser therapy systems are available in several different wavelengths and colors
A lot depends on what you are trying to heal.  Each color reacts differently with the body.
Red lasers (660 nm) can penetrate more deeply, but are still generally used for surface conditions such as healing surface wounds such as bed-sores or diabetic ulcers,burns, acne, and hair restoration.

infrared lasers (905 nm) penetrate much deeper and are used to help heal muscle, ligament, and even bone.
The health benefits of cold laser therapy can be roughly divided into three categories:
1)    Reduce inflammation
2)    Reduce pain
3)    Accelerate tissue repair


 Laser Acupuncture
An increasing body of evidence suggests that laser treatments on specific acupuncture points can stimulate a similar effect as acupuncture needles.The use of laser acupuncture in the ears to help addiction and weight management cases


 Dangers & Risks 
One of the greatest risks of laser therapy is damage to the eyes.  Cold-laser therapy treatments should always be conducted with proper safety glasses worn by both the patient and the practitioner.  Other contraindications for laser treatment include:
• No treatment over suspect tumors or cancer cells
• No treatment over the thyroid

• No treatment over the fontanelle of infants
• No treatment if the patient is using photo-sensitive or immunosuppressant drugs.

These potential risks are a conservative precaution. Special exceptions are already being discovered including the use of laser-therapy to help with macular degeneration

Checklist to laser therapy
Adherence to the laser dosage recommendations from the world association for laser therapy is very important: the eight most important beam parameters  are: wavelength, power, irradiation time, beam area at the skin or culture surface , pulse parameters, anatomical location, number of treatments, and interval between treatments.

The three commonly used dose parameters are time, energy, and energy density.
In addition coherence, application technique(contact, projection, scanning, pressure), beam profile, and spectral width may also be considered important.
Beam power often decreases as the device warms up and as the device ages


coldllaser-thereapy

For further information please call 1-866-843-5273 or visit www.theralase.com

Friday, April 19, 2013

Theralase’s Innovative Anti-Cancer Technology Validated at Major International Conferences


Toronto, Ontario – April 19, 2013 -- Theralase Technologies Inc. (TSX-V: TLT) announced today that its innovative Photo Dynamic Compound (PDC) technology has been accepted for presentation at two major international scientific conferences. Acceptance at these conferences validates the significance of the technology and its efficacy in the destruction of cancer cells in research performed by Theralase's internationally acclaimed scientists.

The efficacy of the anti-cancer Photo Dynamic Compound technology will be presented at LASER World of Photonics conference in Munich, Germany on May 15, 2013.

The effective destruction of bacteria using Theralase’s light activated Photo Dynamic Compound technology will be presented at Photonics North conference in Ottawa, Canada on June 3, 2013.

In further developments, Theralase’s Chief Scientific Officer, Dr. Arkady Mandel has been elected to the Editorial Board of Photonics & Lasers in Medicine (PLM) journal and chosen as issue editor of PLM for the Low Level Laser Therapy (LLLT) issue. PLM is an internationally peer-reviewed journal, which publishes clinical and scientific studies concerned with the clinical and scientific application of lasers and biophotonics in medicine for diagnostic and therapeutic purposes. PLM recently featured the clinical success of Theralase’s pivotal randomized placebo controlled clinical trial entitled, “Laser Therapy Applications for Osteoarthritis and Chronic Joint Pain.”

Roger Dumoulin-White, President and CEO of Theralase said, "I am pleased that Theralase’s scientific and clinical research has been recognized and acclaimed by two of the finest international scientific conferences and has been published in a peer reviewed medical journal. Theralase is committed to the early commercialization of its patented light activated Photo Dynamic Compounds in the areas of anti-cancer and anti-bacterial applications to generate substantial revenue increases for the Company. To accelerate this process, we are actively looking to collaborate with strategic partners to further develop our technologies and increase shareholder value. Theralase’s strong PDC pipeline has scientifically proven that our PDC technology is capable of consistently producing cell kill levels of 100%, even at very low concentrations, across a wide range of cancers and bacteria. In fact, our PDCs have been proven to be significantly more effective in destroying cancer cells and bacteria than currently FDA approved Photo Dynamic Compounds.”

About Theralase Technologies Inc.:
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary laser technology.

 For further information please visit www.theralase.com , regulatory filings may be viewed by visiting www.sedar.com.
 
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information
Roger Dumoulin-White                                                                     
President & CEO                    
416-699-LASE (5273) ext. 225                                   
rwhite@theralase.com

Kristina Hachey
Chief Financial Officer
416-699-LASE (5273) ext. 224
khachey@theralase.com 

Arkady Mandel
Chief Scientific Officer
416-699-LASE (5273) ext. 260
amandel@theralase.com

Greg Bewsh
Director of Investor Relations
416-699-LASE (5273) ext. 258
gbewsh@theralase.com   

Friday, April 12, 2013

TSX Venture Exchange Has Consented to the Extension of Warrants


THERALASE TECHNOLOGIES INC. ("TLT")
BULLETIN TYPE:  Warrant Term Extension
BULLETIN DATE:  April 11, 2013
TSX Venture Tier 2 Company
TSX Venture Exchange has consented to the extension in the expiry date of the following warrants:
Private Placement:
# of Warrants: 
Original Expiry Date of Warrants:
New Expiry Date of Warrants:
Exercise Price of Warrants: 
          1,500,000
April 13, 2013
April 13, 2017
$0.38
            
These warrants were issued pursuant to a private placement of 3,000,000 shares with 1,500,000 share purchase warrants attached, which was accepted for filing by the Exchange effective April 16, 2012.
For further information please call 1-866-843-5273 or visit www.theralase.com 

Monday, April 1, 2013

Theralase Applies to TSX Venture Exchange for Warrant Extension


Toronto, ON – March 28, 2013 - Theralase Technologies Inc. (TSXV: TLT) (“Theralase”) announced today that it has made application to the TSX Venture Exchange for approval to extend the expiry date of its outstanding common share purchase warrants.

Theralase has applied to have the expiry date of the warrants amended from April 13, 2013 to April 13, 2017 for the 1,500,000 total warrants issued on April 13, 2012. The exercise price of the warrants remains unchanged at $0.38 per warrant, with the exception that the warrants will be cancelled if they are not exercised within thirty (30) days from written notice that the closing price of Theralase’s  common shares had been $0.75 or greater for 10 consecutive trading days.

About Theralase Technologies Inc.:
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. Theralase is currently developing proprietary Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technology.

For further information please visit www.theralase.com , regulatory filings may be viewed by visiting www.sedar.com.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information:
Roger Dumoulin-White                                                                     
President & CEO                    
416-699-5273 ext. 225                                  

Kristina Hachey
Chief Financial Officer
416-699-5273 ext. 224

Greg Bewsh
Director of Investor Relations
416-699-5273 ext. 258

Wednesday, February 27, 2013

Low Level Laser in the Treatment of Migraine and Traumatic Brain Injury in the Adult population


Pratibha Bansal M.D.,   Romanth Waghmarae M.D. DABA, FIPP. , Louis Banas B.S. , M.S. CLT ; Buffalo, New York,  June 2012

Note: Dr’s Bansal and Waghmarae are Board Certified Pain Management Physicians who have practicing Pain Management in Buffalo, New York for over 20 years.   Louis Banas is a laser specialist who has treated over 2500 hundred patients for chronic pain issues. He has treated over 60 adults for headaches of various types with significant success in most cases.   


Abstract:

Migraine headache due to trauma or otherwise is a major health concern worldwide with massive financial and social impact. Conventional treatments primarily focus on the prevention of further damage to the brain parenchyma, while failing to address the already existent symptoms. Previous clinical studies have shown that Low Level Laser Therapy (LLLT) can significantly reduce pain and induce temporary vasodilation in capillaries.  The authors demonstrate how LLLT can be used to improve the quality of life in patients by treating their current symptoms,. This case report illustrates the use of LLLT in the treatment of several patients with a severe headache and the clinical success achieved in the reduction of pain, as measured by VAS - achievable within 2-8 treatments.
Abstract:




Objective Information and Background.

The following case studies were followed at a Pain Management Clinic in Buffalo New York.  Pain Rehab is staffed with two board certified Pain Management Specialists who will see 300 to 400 patients weekly. Most patients were being seen do to traumatic injuries suffered at work, home or auto accident and in most cases had little or no relief with physical therapy, chiropractic, massage or surgery. Pain Rehab is very progressive in utilizing new and proven technology and reluctantly prescribes opiates and NSAIDS . All patients suffered from moderate to severe, debilitating pain on a daily basis. After a very positive evaluation of laser therapy on patients, a physical therapy clinic was added to the practice, therefore enabling this new modality to be readily available to their patients. Several patients suffering from chronic, debilitating headaches due to trauma or congenital defects were treated during a four month period. (It is important to note that headaches were just part of the overall pain complaints except for two patients noted in cases 4 and 7.) Over twenty patients were treated and only two patients out of twenty did not respond well. The treatments were performed by a laser specialist with four years of laser experience.  Listed below are a few of the significant, more interesting cases.

Case # 1.  A 28 y.o. female suffered severe whiplash in an auto injury and complained of daily, severe headaches with a vas value of 7-8 accompanied by blurred vision for a 12 month period. Laser was applied to bilateral temples and mastoid   for 2 minutes, delivering 15 joules to five sites, which included bilateral temple and mastoid sites and right cervical spine.  Patient was not able tolerate minimal cervical spine treatment. , including 6 joules per site for a 3 minute duration.  Note: Patient is African American and due to nerve damage or skin pigmentation could not tolerate prescribed dosage.   Treatment was given 3 times per week for two weeks at a reduced dosage for a total of six treatments.  Pain levels were substantially reduced and patient now only suffers 2-3 episodes per week with a vas value of 2-3.

Case #2 .  38 y.o. female, auto injury.  Previous physical therapy was unsuccessful. Patient complained of daily headaches 7-8 on the vas scale for two years.  Treatment included bilateral c-spine and right trapezium for 3 minutes time delivering 42.5 joules to each site, for a period of two weeks and levels increase to 72 joules for second week as patient healed and was more able to tolerate the procedure.  Patient received 12 treatments over a three week period and now experiences mild to moderate headaches once or twice per month.

Case 3#.  58 y.o. male was injured on the job and suffered a severe neck and left clavicle injury. Headaches were daily which were debilitating and patient reported a 7-8 level on the vas scale. Treatments of 8 sessions included 76.5 joules applied to left cervical spine and clavicle. 15 joules were applied to left cervical 1 area, after 10 treatments the headaches were entirely eliminated.

Case # 4. A 23 y.o. Female suffered from headaches 3-4 times per week since six years of age.  Patient has a high stress job as customer service representative. One treatment was applied at both temples delivering 15 joules in a two minute session. Patient was headache free for one week. 

Case#5.  A  57 y.o. female, auto injury 17 years ago and had damage to both frontal lobes. 28 Joules was applied to her forehead at two sites. Due to transportation difficulties her treatments are sporadic but after two treatments she now wakes up with minimal or no pain on most mornings.

Case #6.  A 52 y.o. male fell at work and hit back of head. Headaches occur on daily basis since accident 4 months ago.  Two treatments were performed two days apart delivering 25 joules to injured area. Patient states that headaches are significantly reduced and sleep patterns are substantially improved.

Case # 7. A 31 y.o. female former military P.A. presented herself with migraine headaches with a vas value of 7-8 on a daily basis. She has suffered with them since the age of 8.  The patient had seen several specialists including neurologists who were unable to help. The patient had military training as a physician’s assistant and realized she needed detoxing from drug overload which had been prescribed for the problem.   A single laser treatment was administered which included  48 joules at 2 sites on the forehead and 28 joules to four sites which included bilateral temple and mastoid areas.  The patient had significant relief for a 7 day period at which point she felt the change in medications was to blame. She returned for a single visit one day after the relapse and the  procedure was repeated.  The patient reported to be pain free within minutes after the procedure.  She feels she is completely healed.


Technical data:

The system utilized is the Theralase super pulsed Low Level Laser medical system. It  The system is equipped with a multiple probe hand piece (5 x 905 nm wavelength @0-100 mw average power per laser diode and 4 x 660 nm wavelength @25 mw . power per laser diode. (This allows for deep penetration of tissue when necessary with minimal heat transference to the tissue).

Healing pathways- Discussion

The majority of patients seen in this clinic have multiple injuries and headaches are a by-product of some type of trauma. Therefore, it may be safe to assume that vascular insufficiency is the main cause. A recently published a peer review paper concludes that the equipment used utilizes a 905 nm. Wavelength increasing Nitric acid up to 700 percent which expands capillary delivery of oxygenated blood. Currently Dr. Michael Whalen, working at Massachusetts General Hospital, is conducting controlled studies using a low level laser with the hopes of bringing this new technology into the forefront of neuroscience and medicine. These case studies give examples of how LLLT can be used to treat chronic migraines, specifically those that are a result of traumatic brain injuries. LLLT has been shown to reduce pain and inflammation, create a state of vasodilation by activating the nitric oxide pathway and further even promote angiogenesis.

ATP production.  Cold laser has the unique ability to generate the production of ATP Adenosine Tri-phosphate through a process called biostimualtion. Vacuoles (cytochromes and chromaphores) in the mitochondria of the cell absorb specific light wavelengths causing a cascade effect which rejuvenates damaged cells lacking this essential fuel molecule. Although this may be the main pathway for treating the traumatic injures, it is arguable that the nitric oxide production is the primary source of pain reduction.

Summary. LLLT is now becoming a valuable but slowly recognized modality for acute and chronic pain as well as wound care in the United States. It has been used extensively in Canada for over 12 years.



REFERENCES
1.            Faul M, X.L., Wald MM, Coronado VG, Traumatic brain injury in the United States: emergency department visits, hospitalizations, and deaths. 2010.
2.            Finkelstein E, C.P., Miller T and associates, The Incidence and Economic Burden of Injuries in the United States. Oxford University Press, 2006.
3.            Sahni, T., et al., Use of hyperbaric oxygen in traumatic brain injury: retrospective analysis of data of 20 patients treated at a tertiary care centre. Br J Neurosurg, 2012. 26(2): p. 202-7.
4.            Naeser, M.A. and M.R. Hamblin, Potential for transcranial laser or LED therapy to treat stroke, traumatic brain injury, and neurodegenerative disease. Photomed Laser Surg, 2011. 29(7): p. 443-6.
5.            Moriyama, Y., et al., In vivo effects of low level laser therapy on inducible nitric oxide synthase. Lasers Surg Med, 2009. 41(3): p. 227-31.
6.            Wu, Q., et al., Low-level laser therapy for closed-head traumatic brain injury in mice: effect of different wavelengths. Lasers Surg Med, 2012. 44(3): p. 218-26.

7.             Stephan, W. et al . Efficacy of super –pulsed 905 nm Low Level Laser Therapy in the Management of
Traumatic Brain Injury (TBI) World Journal of Neuroscience November 2012  www.scirp.org/journal/wjnsl



For further information, please visit www.theralase.com or call 1-855-494-7246

Friday, February 1, 2013

Theralase Expands Board of Directors with Strong Financing Capabilities


Toronto, Ontario – February 1, 2013 -- Theralase Technologies Inc. (TSX-V: TLT) announced that effective today Mr. Matthew Perraton PFP, FMA, FCSI and Mr. Guy J. Anderson BA, CFP, CIM, FMA, FCSI, MBA have agreed to serve on the company's Board of Directors.

Mr. Perraton and Mr. Anderson join Mr. Donald Moore, Mr. Randy Bruder and Mr. Roger Dumoulin-White on the board and will be instrumental in helping Theralase secure the financing required to fuel Theralase’s growth over the next 5 to 10 years.

Mr. Perraton brings over 13 years of financial experience to Theralase, most recently as a Financial Planner for TD Waterhouse. Prior to his current position, Mr. Perraton held progressively higher positions with BMO Nesbitt Burns and Bank of Nova Scotia.

Mr. Perraton stated that, “I am delighted to join the board at Theralase, as I am absolutely convinced that Theralase is on the right path for shareholder value with both their therapeutic laser technology for healing tissue and their Photo Dynamic Compound (PDC) technology for destroying cancer. Their technology is far superior to anything I have seen on the market and properly financed I see great opportunities for Theralase in the near term”.

Mr. Anderson brings over 16 years of financial experience to Theralase, most recently as a Wealth Management and Personal Finance Advisor with the Investment Planning Counsel. Prior to his current position, Mr. Anderson held progressively higher positions with Franklin Templeton Investments Canada, T.E. Financial and Bank of Nova Scotia.

Mr. Anderson stated that, “I have followed the progress of Theralase over the last 4 to 5 years and have been amazed that the company has been able to advance such cutting-edge technology on a shoe string budget. I join Matt in saying that properly capitalized there is nothing that stands in the way of Theralase’s success. Their technology is not only the best on the market, but their management team has demonstrated an ability to survive in choppy markets and to advance the technology to the point that it is ready to grow in leaps and bounds”.

Roger Dumoulin-White, President and CEO, Theralase Technologies Inc. stated, “I am pleased that Matt and Guy have agreed to serve on our Board of Directors. They both have broad experience in financial management, regulatory compliance and strategic planning and both possess the vision and financial acumen to drive Theralase forward to achieve our full potential. I welcome Matt and Guy to the board and am confident that both will serve the company and the shareholders well during their tenure.”

Mr. Dumoulin-White also stated, “We are all saddened by the loss of our long time board member Mr. John “Jack” Murphy late last year  and we would like to take this opportunity to express our profound condolences to Jack’s family. He was a strong member of our team, an insightful director and always a pleasure to work with. His business judgment and knowledge will be sorely missed”.

About Theralase Technologies Inc.:
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technology.

 For further information please visit www.theralase.com , regulatory filings may be viewed by visiting www.sedar.com.
 
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information
Roger Dumoulin-White                                                                     
President & CEO                    
416-694-7246 ext. 225                                  
rwhite@theralase.com

Kristina Hachey
Chief Financial Officer
416-694-7246 ext. 224
khachey@theralase.com 

Arkady Mandel
Chief Scientific Officer
416-694-7246 ext. 242
amandel@theralase.com

Greg Bewsh
Director of Investor Relations
416-694-7246 ext. 258
gbewsh@theralase.com   

Tuesday, January 29, 2013

Renowned Oncologist Dr. Michael Jewett Joins Theralase’s Medical and Scientific Advisory Board


Toronto, Ontario –January 29, 2013 -- Theralase Technologies Inc. (TSX-V: TLT) is pleased to announce that effective January 15, 2013, Michael Jewett MD, FRCSC, FACS has elected to join its Medical and Scientific Advisory Board.

Dr. Michael Jewett is currently a Professor of Surgery in the Division of Urology at the University of Toronto, a member of the Department of Surgical Oncology at Princess Margaret Cancer Centre and of the Division of Urology at the University Health Network. He is well known for his contributions in the fields of technology assessment and image guided therapy, especially for minimally invasive treatment of kidney and bladder cancer. He is internationally known for his contributions in the fields of bladder, testis and kidney cancer fundamental and clinical research. For his valued contributions to the uro-oncology field, in 2008, Dr. Jewett was awarded the Wyeth/CIHR Rx&D Clinical Research Chair in Oncology. He also holds the Farquaharson Chair for Kidney Cancer Research.

Dr. Jewett has been the Principal Investigator/Co-Principal Investigator on over 60 Phase I-Phase III clinical trials and the Lead Principal Investigator of several Cooperative Group Trials. These clinical trials have primarily been focused on proving the safety, efficacy and clinical benefits of technology in the destruction of cancer, with the ultimate gain of achieving Health Canada or FDA clinical approval. 

He has recently served as Chairman of the Division of Urology at the University of Toronto and of Urology at the University Health Network, which incorporates the Princess Margaret Cancer Centre, one of the world's leading cancer centres. He is a recent Past-President of the Canadian Urology Association and a member of many urological and surgical oncology societies; including the Scientific Advisory Board of the Bladder Cancer Advocacy Network, the Medical Advisory and Research Board of Bladder Cancer Canada, and Chair of the CIHR funded Kidney Cancer Research Network of Canada. Dr. Jewett has been recognized for his lifetime achievements and contributions to Urology by the Canadian Urological Association, the American Urological Association, the Societe Internationale d’Urologie and the Society of Urologic Oncology.

Dr. Jewett stated, “I have been very impressed with the expertise of the Theralase team and with the significant opportunity their Photo Dynamic Compounds (PDCs) present in the field of bladder cancer treatment. I look forward to working with them closely in their quest to commercialize their PDC technology to the ultimate benefit of bladder cancer patients, when the unmet need remains so great”.

Roger Dumoulin-White, President and CEO, Theralase Technologies Inc. stated that, “We are elated to have someone of Dr. Jewett’s calibre join Theralase’s Medical and Scientific Advisory Board to lead our bladder cancer clinical research program. He has been actively engaged in clinical cancer research and will prove to be an invaluable resource for helping to design our clinical protocols, in conjunction with our research team, as we focus on our lead target, bladder cancer. With Dr. Jewett’s expert guidance, we are confident that we will be able to complete the steps necessary to commence FDA Phase 1 human clinical trials in 2013 with our lead Photo Dynamic Compound (PDC), where we will demonstrate that Theralase possesses a highly effective and safe alternative treatment option to patients, suffering from non-muscle invasive bladder cancer. Based on the clinical success of the PDC technology in FDA Phase 1 human clinical trials, Theralase is expected to be granted FDA “Fast Track” designation allowing an expedited priority review and approval process.”

According to the FDA, “Fast Track” is a process designed to facilitate the development and expedite the review of drugs to treat serious diseases and fill an unmet medical need. The purpose is to get important new drugs to the patient earlier.

About Theralase Technologies Inc.:
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technology.

 For further information please visit www.theralase.com , regulatory filings may be viewed by visiting www.sedar.com.
 
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information:
Roger Dumoulin-White                                                                     
President & CEO                    
416-694-7246 ext. 225                                  
rwhite@theralase.com

Kristina Hachey
Chief Financial Officer
416-694-7246 ext. 224
khachey@theralase.com 

Arkady Mandel
Chief Scientific Officer
416-694-7246 ext. 242
amandel@theralase.com

Greg Bewsh
Director of Investor Relations
416-694-7246 ext. 262
gbewsh@theralase.com